{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T11:48:50Z","timestamp":1778500130368,"version":"3.51.4"},"reference-count":82,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2004,8,1]],"date-time":"2004-08-01T00:00:00Z","timestamp":1091318400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T00:00:00Z","timestamp":1578355200000},"content-version":"vor","delay-in-days":5637,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2004,8]]},"DOI":"10.1093\/annonc\/mdh300","type":"journal-article","created":{"date-parts":[[2004,7,26]],"date-time":"2004-07-26T22:40:48Z","timestamp":1090881648000},"page":"1151-1160","source":"Crossref","is-referenced-by-count":94,"title":["Thalidomide in cancer medicine"],"prefix":"10.1016","volume":"15","author":[{"given":"V.","family":"Eleutherakis-Papaiakovou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Bamias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.A.","family":"Dimopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdh300_bb0010","doi-asserted-by":"crossref","first-page":"4082","DOI":"10.1073\/pnas.91.9.4082","article-title":"Thalidomide is an inhibitor of angiogenesis","volume":"91","author":"D'Amato","year":"1994","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1093\/annonc\/mdh300_bb0015","first-page":"177","article-title":"Immunomodulation by thalidomide: systemic review of the literature and of unpublished observations","volume":"46","author":"Zwingenberger","year":"1995","journal-title":"J Inflamm"},{"key":"10.1093\/annonc\/mdh300_bb0020","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1146\/annurev.med.53.082901.104043","article-title":"Thalidomide: emerging role in cancer medicine","volume":"53","author":"Richardson","year":"2002","journal-title":"Annu Rev Med"},{"key":"10.1093\/annonc\/mdh300_bb0025","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/S0093-7754(01)90032-6","article-title":"Thalidomide: a novel template for anticancer drugs","volume":"28","author":"Stirling","year":"2001","journal-title":"Semin Oncol"},{"key":"10.1093\/annonc\/mdh300_bb0030","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1021\/js980172i","article-title":"Pharmacokinetics of thalidomide in an elderly prostate cancer population","volume":"88","author":"Figg","year":"1999","journal-title":"J Pharm Sci"},{"key":"10.1093\/annonc\/mdh300_bb0035","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1016\/S0006-2952(98)00046-X","article-title":"Inhibition of angiogenesis requires metabolic activation, which is species-dependent","volume":"55","author":"Bauer","year":"1998","journal-title":"Biochem Pharmacol"},{"key":"10.1093\/annonc\/mdh300_bb0040","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1084\/jem.177.6.1675","article-title":"Thalidomide exerts its inhibitory action on tumor necrosis factor \u03b1 by enhancing mRNA degradation","volume":"177","author":"Moreira","year":"1993","journal-title":"J Exp Med"},{"key":"10.1093\/annonc\/mdh300_bb0045","doi-asserted-by":"crossref","first-page":"22383","DOI":"10.1074\/jbc.M100938200","article-title":"Inhibition of NF-kappa B activity by thalidomide through suppression of I kappa B kinase activity","volume":"276","author":"Keifer","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1093\/annonc\/mdh300_bb0050","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/0162-3109(95)00050-X","article-title":"Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade","volume":"31","author":"Geitz","year":"1996","journal-title":"Immunopharmacology"},{"key":"10.1093\/annonc\/mdh300_bb0055","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0149-2918(00)88289-2","article-title":"STEPS: a comprehensive program for controlling and monitoring access to thalidomide","volume":"21","author":"Zeldis","year":"1999","journal-title":"Clin Ther"},{"key":"10.1093\/annonc\/mdh300_bb0060","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3816\/CLM.2003.n.011","article-title":"Thalidomide and deep vein thrombosis in multiple myeloma: risk factors and effect on survival","volume":"4","author":"Zangari","year":"2003","journal-title":"Clin Lymphoma"},{"key":"10.1093\/annonc\/mdh300_bb0065","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1046\/j.1365-2141.2003.03902.x","article-title":"Thalidomide in multiple myeloma: current status and future prospects","volume":"120","author":"Cavenagh","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdh300_bb0070","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1212\/01.WNL.0000037480.59194.85","article-title":"Thalidomide-induced neuropathy","volume":"59","author":"Chauhry","year":"2002","journal-title":"Neurology"},{"key":"10.1093\/annonc\/mdh300_bb0075","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1002\/mus.1109","article-title":"Thalidomide neuropathy in patients treated for metastatic prostate cacer","volume":"24","author":"Molloy","year":"2001","journal-title":"Muscle Nerve"},{"key":"10.1093\/annonc\/mdh300_bb0080","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","article-title":"Antitumor activity of thalidomide in refractory multiple myeloma","volume":"341","author":"Singhal","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdh300_bb0085","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1182\/blood.V98.2.492","article-title":"Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification and prognostic factors in a phase 2 study of 169 patients","volume":"98","author":"Barlogie","year":"2001","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdh300_bb0090","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/S0145-2126(03)00027-4","article-title":"An U.K. Myeloma Forum phase II study of thalidomide; long term follow-up and recommendations for treatment","volume":"27","author":"Schey","year":"2003","journal-title":"Leuk Res"},{"issue":"Suppl 1","key":"10.1093\/annonc\/mdh300_bb0095","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S0037-1963(00)90079-9","article-title":"Thalidomide for resistant and relapsing myeloma","volume":"37","author":"Alexanian","year":"2000","journal-title":"Semin Hematol"},{"key":"10.1093\/annonc\/mdh300_bb0100","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1023\/A:1011132808904","article-title":"Thalidomide and dexamethasone combination for refractory multiple myeloma","volume":"12","author":"Dimopoulos","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdh300_bb0105","first-page":"399","article-title":"Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma","volume":"86","author":"Palumbo","year":"2001","journal-title":"Haematologica"},{"key":"10.1093\/annonc\/mdh300_bb0110","doi-asserted-by":"crossref","first-page":"3846","DOI":"10.1182\/blood.V98.13.3846","article-title":"Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy","volume":"98","author":"Moehler","year":"2001","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdh300_bb0115","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1046\/j.1365-2141.2003.04473.x","article-title":"Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma","volume":"122","author":"Kropff","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdh300_bb0120","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1200\/JCO.2003.01.055","article-title":"DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma","volume":"21","author":"Lee","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdh300_bb0125","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/sj.leu.2402866","article-title":"Thalidomide as initial therapy for early-stage myeloma","volume":"17","author":"Rajkumar","year":"2003","journal-title":"Leukemia"},{"key":"10.1093\/annonc\/mdh300_bb0130","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1200\/JCO.2003.03.139","article-title":"Thalidomide alone or with dexamethasone for previously untreated multiple myeloma","volume":"21","author":"Weber","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdh300_bb0135","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1200\/JCO.2002.02.116","article-title":"Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma","volume":"20","author":"Rajkumar","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdh300_bb0140","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1093\/annonc\/mdh026","article-title":"Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study","volume":"15","author":"Zervas","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdh300_bb0145","first-page":"148a","article-title":"Oral melphalan prednisone and thalidomide for newly diagnosed myeloma","volume":"102","author":"Palumbo","year":"2003","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdh300_bb0150","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1182\/blood.V98.5.1614","article-title":"Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy","volume":"98","author":"Zangari","year":"2001","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdh300_bb0155","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1093\/annonc\/mdf188","article-title":"Consolidation therapy of multiple myeloma with thalidomide-dexamethasone after intensive chemotherapy","volume":"13","author":"Alexanian","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdh300_bb0160","first-page":"691a","article-title":"Thalidomide maintenance following high dose therapy in multiple myeloma: a UK Myeloma Forum phase 2 study","volume":"102","author":"Feyler","year":"2003","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdh300_bb0165","doi-asserted-by":"crossref","first-page":"3596","DOI":"10.1200\/JCO.2001.19.16.3596","article-title":"Treatment of Waldenstrom's macroglobulinemia with thalidomide","volume":"19","author":"Dimopoulos","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdh300_bb0170","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1053\/sonc.2003.50079","article-title":"Treatment of Waldenstrom's macroglobulinemia with single agent thalidomide or with the combination of clarythromycin, thalidomide and dexamethasone","volume":"30","author":"Dimopoulos","year":"2003","journal-title":"Semin Oncol"},{"key":"10.1093\/annonc\/mdh300_bb0175","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3816\/CLM.2003.n.005","article-title":"Tolerability and efficacy of thalidomide for the treatment of patients with AL amyloidosis","volume":"3","author":"Seldin","year":"2003","journal-title":"Clin Lymphoma"},{"key":"10.1093\/annonc\/mdh300_bb0180","first-page":"397a","article-title":"Thalidomide toxicity in patients with AL (primary) amyloidosis","volume":"100","author":"Palladini","year":"2002","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdh300_bb0185","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1046\/j.1365-2141.2001.02918.x","article-title":"Safety and efficacy of thalidomide in patients with myelofibrosis and myeloid metaplasia","volume":"114","author":"Barosi","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdh300_bb0190","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1046\/j.1365-2141.2001.03072.x","article-title":"Thaldomide in agnogenic and secondary myelofibrosis","volume":"115","author":"Canepa","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdh300_bb0195","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1046\/j.1365-2141.2002.03443.x","article-title":"Thalidomide treatment in myelofibrosis with myeloid metaplasia","volume":"117","author":"Elliott","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdh300_bb0200","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1038\/sj.leu.2402596","article-title":"Clinical efficacy and antiangiogenic activity of thalidomide in myelofibrosis with myeloid metaplasia: a pilot study","volume":"16","author":"Piccaluga","year":"2002","journal-title":"Leukemia"},{"key":"10.1093\/annonc\/mdh300_bb0205","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1182\/blood-2002-09-2928","article-title":"A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia","volume":"101","author":"Mesa","year":"2003","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdh300_bb0210","first-page":"33a","article-title":"Durable and unmaintained remissions with thalidomide-based drug therapy in myelofibrosis with myeloid metaplasia long term analysis of two prospective studies","volume":"102","author":"Mesa","year":"2001","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdh300_bb0215","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1182\/blood.V98.4.958","article-title":"Dutto et al. Thalidomide produces transfusion-independence in long-standing refractory anemias of patients with myelodysplastic syndromes","volume":"98","author":"Raza","year":"2001","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdh300_bb0220","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1046\/j.1365-2141.2001.03204.x","article-title":"The clinical and biological effects of thalidomide in patients with myelodysplastic syndromes","volume":"115","author":"Zorat","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdh300_bb0225","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/sj.leu.2402330","article-title":"Thalidomide for the treatment of patients with myelodysplastic syndromes","volume":"16","author":"Strupp","year":"2002","journal-title":"Leukemia"},{"key":"10.1093\/annonc\/mdh300_bb0230","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1046\/j.1365-2141.2003.04252.x","article-title":"Thromboembolic events in patients with myelodysplastic syndrome receiving thalidomide in combination with darbepoetin-\u03b1","volume":"121","author":"Steurer","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdh300_bb0235","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1002\/cncr.11180","article-title":"A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myeloid leukemia or myelodysplastic syndrome","volume":"97","author":"Cortes","year":"2003","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdh300_bb0240","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1182\/blood.V99.3.834","article-title":"Efficacy and safety of thalidomide in patients with acute myeloid leukemia","volume":"99","author":"Steins","year":"2002","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdh300_bb0245","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1046\/j.1365-2141.2003.04639.x","article-title":"Simple agent thalidomide in patients with relapsed or refractory acute myeloid leukemia","volume":"123","author":"Thomas","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdh300_bb0250","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1200\/JCO.2000.18.4.708","article-title":"Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas","volume":"18","author":"Fine","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdh300_bb0255","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1023\/A:1006414804835","article-title":"Thalidomide as an antiangiogenic agent in relapsed gliomas","volume":"51","author":"Short","year":"2001","journal-title":"J Neurooncol"},{"key":"10.1093\/annonc\/mdh300_bb0260","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1023\/A:1012554328801","article-title":"Phase II study of thalidomide in the treatment of recurrent glioblastoma multiforme","volume":"54","author":"Marx","year":"2001","journal-title":"J Neurooncol"},{"key":"10.1093\/annonc\/mdh300_bb0265","first-page":"140a","article-title":"Phase I\/II study of carboplatin and thalidomide in recurrent glioblastoma multiforme","volume":"18","author":"Glass","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdh300_bb0270","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1200\/JCO.2003.08.045","article-title":"Phase\u2009II trial of thalidomide and carmustine for patients with recurrent high grade gliomas","volume":"21","author":"Fine","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdh300_bb0275","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1054\/bjoc.2001.2025","article-title":"The treatment of advanced renal cell cancer with high dose oral thalidomide","volume":"85","author":"Stebbing","year":"2001","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdh300_bb0280","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1200\/JCO.20.1.302","article-title":"Phase II trial of thalidomide for patients with advanced renal cell carcinoma","volume":"20","author":"Motzer","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdh300_bb0285","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1093\/annonc\/mdf213","article-title":"Phase II trial of thalidomide in renal-cell carcinoma","volume":"13","author":"Escudier","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdh300_bb0290","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1002\/cncr.10740","article-title":"A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma","volume":"95","author":"Daliani","year":"2002","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdh300_bb0295","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1023\/A:1020669705369","article-title":"A phase II study of thalidomide in advanced metastatic renal cell carcinoma","volume":"20","author":"Minor","year":"2002","journal-title":"Invest New Drugs"},{"key":"10.1093\/annonc\/mdh300_bb0300","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1054\/bjoc.1999.1004","article-title":"Continuous low dose thalidomide: a phase II study in advanced melanoma, renal cell ovarian and breast cancer","volume":"82","author":"Eisen","year":"2000","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdh300_bb0305","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1200\/JCO.2002.20.5.1429","article-title":"Unexpected toxicity of combination thalidomide and interferon \u03b1-2a treatment in metastatic renal cell carcinoma","volume":"20","author":"Nathan","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdh300_bb0310","doi-asserted-by":"crossref","first-page":"3770","DOI":"10.1200\/JCO.2003.01.536","article-title":"Interferon \u03b1-2b three times daily and thalidomide in the treatment of metastatic renal cell carcinoma","volume":"21","author":"Hernberg","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdh300_bb0315","first-page":"387a","article-title":"Phase II study of thalidomide plus interleukin-2 in patients with metastatic renal cell carcinoma","volume":"22","author":"Amato","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdh300_bb0320","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1016\/S1040-8428(03)00064-7","article-title":"Current status of thalidomide and its role in the treatment of metastatic prostate cancer","volume":"46","author":"Macpherson","year":"2003","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1093\/annonc\/mdh300_bb0325","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/sj.bjc.6600817","article-title":"An open-label phase II study of low-dose thalidomide in androgen-independent prostate cancer","volume":"88","author":"Drake","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdh300_bb0330","first-page":"1888","article-title":"A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer","volume":"7","author":"Figg","year":"2001","journal-title":"Clin Cancer Res"},{"issue":"4 Suppl 15","key":"10.1093\/annonc\/mdh300_bb0335","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/S0093-7754(01)90157-5","article-title":"A randomized phase II trial of docetaxel (Taxotere\u00ae) plus thalidomide in androgen-independent prostate cancer","volume":"28","author":"Figg","year":"2001","journal-title":"Semin Oncol"},{"key":"10.1093\/annonc\/mdh300_bb0340","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1200\/JCO.2002.09.034","article-title":"Temozolomide plus thalidomide in patients with advanced melanoma: results of a dose-finding trial","volume":"20","author":"Hwu","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdh300_bb0345","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1200\/JCO.2003.02.061","article-title":"Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma","volume":"21","author":"Hwu","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdh300_bb0350","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1200\/JCO.2003.10.039","article-title":"Randomized phase II study of temozolomide given every 8 hours or daily with either interferon \u03b1-2b or thalidomide in metastatic malignant melanoma","volume":"21","author":"Danson","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdh300_bb0355","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1258\/0956462981921512","article-title":"Activity of thalidomide in AIDS-related Kaposi's sarcoma and correlation with HHV8 titer","volume":"9","author":"Fife","year":"1998","journal-title":"Int J STD AIDS"},{"key":"10.1093\/annonc\/mdh300_bb0360","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1200\/JCO.2000.18.13.2593","article-title":"Activity of thalidomide in AIDS-related Kaposi sarcoma","volume":"18","author":"Little","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdh300_bb0365","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1200\/JCO.2000.18.14.2710","article-title":"Phase II evaluation of thalidomide in patients with metastatic breast cancer","volume":"18","author":"Baidas","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdh300_bb0370","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1002\/1097-0142(20011101)92:9<2364::AID-CNCR1584>3.0.CO;2-P","article-title":"Phase II study of the antiangiogenic agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck","volume":"92","author":"Tseng","year":"2001","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdh300_bb0375","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1023\/A:1025485031112","article-title":"Phase II trial and pharmacokinetic study of thalidomide in patients with metastatic colorectal cancer","volume":"21","author":"Dal Lago","year":"2003","journal-title":"Invest New Drugs"},{"key":"10.1093\/annonc\/mdh300_bb0380","first-page":"247a","article-title":"Irinotecan and thalidomide prolong disease free and overall survival in 5-FU refractory metastatic colorectal cancer","volume":"22","author":"Govindarajan","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdh300_bb0385","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1159\/000074477","article-title":"Low-dose thalidomide treatment for advanced hepatocellular carcinoma","volume":"65","author":"Hsu","year":"2003","journal-title":"Oncology"},{"key":"10.1093\/annonc\/mdh300_bb0390","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/sj.bmt.1701138","article-title":"The role of thalidomide in the treatment of refractory chronic graft-versus-host disease following bone marrow transplantation in children","volume":"21","author":"Rovelli","year":"1998","journal-title":"Bone Marrow Transplant"},{"key":"10.1093\/annonc\/mdh300_bb0395","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/sj.bmt.1704033","article-title":"Thalidomide after allogenic haematopoietic stem cell transplantation: activity in chronic but not in acute graft-versus-host disease","volume":"32","author":"Kulkarni","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.1093\/annonc\/mdh300_bb0400","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1023\/A:1008329821941","article-title":"Thalidomide in patients with cachexia due to terminal cancer: preliminary report","volume":"10","author":"Bruera","year":"1999","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdh300_bb0405","first-page":"236a","article-title":"VTD regimen comprising velcade plus thalidomide and added dexamethasone for non-responders to V\u2009+\u2009T effects a 57% PR rate among 56 patients with myeloma relapsing after autologous transplant","volume":"102","author":"Zangari","year":"2003","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdh300_bb0410","first-page":"684a","article-title":"Phase I\/II trial of oblimersen sodium, dexamethasone and thalidomide in patients with relapsed multiple myeloma","volume":"102","author":"Badros","year":"2003","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdh300_bb0415","doi-asserted-by":"crossref","first-page":"669","DOI":"10.4161\/cbt.318","article-title":"Pharmacogenetic association of CYP2C19 genotype with in vivo metabolisms and drug effects of thalidomide","volume":"1","author":"Ando","year":"2002","journal-title":"Cancer Biol Ther"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753420310371?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753420310371?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/15\/8\/1151\/334866\/mdh300.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,21]],"date-time":"2020-02-21T03:31:12Z","timestamp":1582255872000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753420310371"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,8]]},"references-count":82,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2004,8]]}},"alternative-id":["S0923753420310371"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdh300","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2004,8]]}}}